Parsons James T. 4

What Happened

• James T. Parsons, a director of Oncolytics Biotech Inc. (ONCY), made an open-market purchase of 10,000 common shares on 2026-03-11.
• The shares were acquired at $1.03 per share for a total transaction value of $10,300. This was a purchase (insider buy), which many investors view as a bullish signal, though it is a modest-sized transaction.

Key Details

• Transaction date: 2026-03-11; price: $1.03 per share; total value: $10,300.
• Transaction code: P (purchase — open market/private purchase).
• Shares owned after the transaction: Not provided in the supplied summary — see the full Form 4 for total holdings.
• Filing date: 2026-03-13 (filed within the usual two-business-day Form 4 reporting window).
• No 10b5-1 plan, tax withholding, or other footnotes were noted in the supplied transaction summary.

Context

• This was a straightforward open-market purchase (not an option exercise, gift, or award). Purchases by insiders can signal confidence, but this amount is relatively small; investors should consider total insider holdings and company news before drawing conclusions.
• For full details (total post-transaction holdings, any footnotes, and exact filing language), consult the SEC Form 4 (Accession 0001493152-26-009983).